The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy
Nitin Kumar,1 Shelby Sullivan,2 Christopher C Thompson3 1Bariatric Endoscopy Institute, Addison, IL, 2Gastroenterology Bariatric and Metabolic Program, University of Colorado School of Medicine, Denver, CO, 3Gastroenterology and Therapeutic Endoscopy, Brigham and Women’s Hospital, Harvard...
Ausführliche Beschreibung
Autor*in: |
Kumar N [verfasserIn] Sullivan S [verfasserIn] Thompson CC [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2017 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Diabetes, Metabolic Syndrome and Obesity - Dove Medical Press, 2009, (2017), Seite 311-316 |
---|---|
Übergeordnetes Werk: |
year:2017 ; pages:311-316 |
Links: |
---|
Katalog-ID: |
DOAJ052342662 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ052342662 | ||
003 | DE-627 | ||
005 | 20230310205246.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2017 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)DOAJ052342662 | ||
035 | |a (DE-599)DOAJeba2a5da1fe44a2e9a271d5ae0596480 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC581-951 | |
100 | 0 | |a Kumar N |e verfasserin |4 aut | |
245 | 1 | 4 | |a The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Nitin Kumar,1 Shelby Sullivan,2 Christopher C Thompson3 1Bariatric Endoscopy Institute, Addison, IL, 2Gastroenterology Bariatric and Metabolic Program, University of Colorado School of Medicine, Denver, CO, 3Gastroenterology and Therapeutic Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Abstract: Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35–55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used extensively outside the USA for over 20 years. These devices will need to be delivered in the context of a multidisciplinary weight loss program, integrating comprehensive care of obesity. Patient selection is important, and ensuring appropriate patient expectations and understanding of alternatives such as pharmacologic therapy and surgery is essential. With several EBTs on the horizon, patients with obesity will have an even broader array of safe and effective options for weight management in the future. Keywords: intragastric balloon, Orbera, ReShape, AspireAssist, aspiration therapy, weight loss | ||
650 | 4 | |a Intragastric balloon | |
650 | 4 | |a aspiration therapy | |
650 | 4 | |a Orbera | |
650 | 4 | |a Reshape | |
650 | 4 | |a Aspire | |
650 | 4 | |a AspireAssist | |
653 | 0 | |a Specialties of internal medicine | |
700 | 0 | |a Sullivan S |e verfasserin |4 aut | |
700 | 0 | |a Thompson CC |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Diabetes, Metabolic Syndrome and Obesity |d Dove Medical Press, 2009 |g (2017), Seite 311-316 |w (DE-627)60030597X |w (DE-600)2494854-8 |x 11787007 |7 nnns |
773 | 1 | 8 | |g year:2017 |g pages:311-316 |
856 | 4 | 0 | |u https://doaj.org/article/eba2a5da1fe44a2e9a271d5ae0596480 |z kostenfrei |
856 | 4 | 0 | |u https://www.dovepress.com/the-role-of-endoscopic-therapy-in-obesity-management-intragastric-ball-peer-reviewed-article-DMSO |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1178-7007 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |j 2017 |h 311-316 |
author_variant |
k n kn s s ss t c tc |
---|---|
matchkey_str |
article:11787007:2017----::hrloedsoiteaynbstmngmnitaatiblo |
hierarchy_sort_str |
2017 |
callnumber-subject-code |
RC |
publishDate |
2017 |
allfields |
(DE-627)DOAJ052342662 (DE-599)DOAJeba2a5da1fe44a2e9a271d5ae0596480 DE-627 ger DE-627 rakwb eng RC581-951 Kumar N verfasserin aut The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Nitin Kumar,1 Shelby Sullivan,2 Christopher C Thompson3 1Bariatric Endoscopy Institute, Addison, IL, 2Gastroenterology Bariatric and Metabolic Program, University of Colorado School of Medicine, Denver, CO, 3Gastroenterology and Therapeutic Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Abstract: Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35–55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used extensively outside the USA for over 20 years. These devices will need to be delivered in the context of a multidisciplinary weight loss program, integrating comprehensive care of obesity. Patient selection is important, and ensuring appropriate patient expectations and understanding of alternatives such as pharmacologic therapy and surgery is essential. With several EBTs on the horizon, patients with obesity will have an even broader array of safe and effective options for weight management in the future. Keywords: intragastric balloon, Orbera, ReShape, AspireAssist, aspiration therapy, weight loss Intragastric balloon aspiration therapy Orbera Reshape Aspire AspireAssist Specialties of internal medicine Sullivan S verfasserin aut Thompson CC verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2017), Seite 311-316 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2017 pages:311-316 https://doaj.org/article/eba2a5da1fe44a2e9a271d5ae0596480 kostenfrei https://www.dovepress.com/the-role-of-endoscopic-therapy-in-obesity-management-intragastric-ball-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2017 311-316 |
spelling |
(DE-627)DOAJ052342662 (DE-599)DOAJeba2a5da1fe44a2e9a271d5ae0596480 DE-627 ger DE-627 rakwb eng RC581-951 Kumar N verfasserin aut The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Nitin Kumar,1 Shelby Sullivan,2 Christopher C Thompson3 1Bariatric Endoscopy Institute, Addison, IL, 2Gastroenterology Bariatric and Metabolic Program, University of Colorado School of Medicine, Denver, CO, 3Gastroenterology and Therapeutic Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Abstract: Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35–55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used extensively outside the USA for over 20 years. These devices will need to be delivered in the context of a multidisciplinary weight loss program, integrating comprehensive care of obesity. Patient selection is important, and ensuring appropriate patient expectations and understanding of alternatives such as pharmacologic therapy and surgery is essential. With several EBTs on the horizon, patients with obesity will have an even broader array of safe and effective options for weight management in the future. Keywords: intragastric balloon, Orbera, ReShape, AspireAssist, aspiration therapy, weight loss Intragastric balloon aspiration therapy Orbera Reshape Aspire AspireAssist Specialties of internal medicine Sullivan S verfasserin aut Thompson CC verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2017), Seite 311-316 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2017 pages:311-316 https://doaj.org/article/eba2a5da1fe44a2e9a271d5ae0596480 kostenfrei https://www.dovepress.com/the-role-of-endoscopic-therapy-in-obesity-management-intragastric-ball-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2017 311-316 |
allfields_unstemmed |
(DE-627)DOAJ052342662 (DE-599)DOAJeba2a5da1fe44a2e9a271d5ae0596480 DE-627 ger DE-627 rakwb eng RC581-951 Kumar N verfasserin aut The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Nitin Kumar,1 Shelby Sullivan,2 Christopher C Thompson3 1Bariatric Endoscopy Institute, Addison, IL, 2Gastroenterology Bariatric and Metabolic Program, University of Colorado School of Medicine, Denver, CO, 3Gastroenterology and Therapeutic Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Abstract: Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35–55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used extensively outside the USA for over 20 years. These devices will need to be delivered in the context of a multidisciplinary weight loss program, integrating comprehensive care of obesity. Patient selection is important, and ensuring appropriate patient expectations and understanding of alternatives such as pharmacologic therapy and surgery is essential. With several EBTs on the horizon, patients with obesity will have an even broader array of safe and effective options for weight management in the future. Keywords: intragastric balloon, Orbera, ReShape, AspireAssist, aspiration therapy, weight loss Intragastric balloon aspiration therapy Orbera Reshape Aspire AspireAssist Specialties of internal medicine Sullivan S verfasserin aut Thompson CC verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2017), Seite 311-316 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2017 pages:311-316 https://doaj.org/article/eba2a5da1fe44a2e9a271d5ae0596480 kostenfrei https://www.dovepress.com/the-role-of-endoscopic-therapy-in-obesity-management-intragastric-ball-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2017 311-316 |
allfieldsGer |
(DE-627)DOAJ052342662 (DE-599)DOAJeba2a5da1fe44a2e9a271d5ae0596480 DE-627 ger DE-627 rakwb eng RC581-951 Kumar N verfasserin aut The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Nitin Kumar,1 Shelby Sullivan,2 Christopher C Thompson3 1Bariatric Endoscopy Institute, Addison, IL, 2Gastroenterology Bariatric and Metabolic Program, University of Colorado School of Medicine, Denver, CO, 3Gastroenterology and Therapeutic Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Abstract: Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35–55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used extensively outside the USA for over 20 years. These devices will need to be delivered in the context of a multidisciplinary weight loss program, integrating comprehensive care of obesity. Patient selection is important, and ensuring appropriate patient expectations and understanding of alternatives such as pharmacologic therapy and surgery is essential. With several EBTs on the horizon, patients with obesity will have an even broader array of safe and effective options for weight management in the future. Keywords: intragastric balloon, Orbera, ReShape, AspireAssist, aspiration therapy, weight loss Intragastric balloon aspiration therapy Orbera Reshape Aspire AspireAssist Specialties of internal medicine Sullivan S verfasserin aut Thompson CC verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2017), Seite 311-316 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2017 pages:311-316 https://doaj.org/article/eba2a5da1fe44a2e9a271d5ae0596480 kostenfrei https://www.dovepress.com/the-role-of-endoscopic-therapy-in-obesity-management-intragastric-ball-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2017 311-316 |
allfieldsSound |
(DE-627)DOAJ052342662 (DE-599)DOAJeba2a5da1fe44a2e9a271d5ae0596480 DE-627 ger DE-627 rakwb eng RC581-951 Kumar N verfasserin aut The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Nitin Kumar,1 Shelby Sullivan,2 Christopher C Thompson3 1Bariatric Endoscopy Institute, Addison, IL, 2Gastroenterology Bariatric and Metabolic Program, University of Colorado School of Medicine, Denver, CO, 3Gastroenterology and Therapeutic Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Abstract: Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35–55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used extensively outside the USA for over 20 years. These devices will need to be delivered in the context of a multidisciplinary weight loss program, integrating comprehensive care of obesity. Patient selection is important, and ensuring appropriate patient expectations and understanding of alternatives such as pharmacologic therapy and surgery is essential. With several EBTs on the horizon, patients with obesity will have an even broader array of safe and effective options for weight management in the future. Keywords: intragastric balloon, Orbera, ReShape, AspireAssist, aspiration therapy, weight loss Intragastric balloon aspiration therapy Orbera Reshape Aspire AspireAssist Specialties of internal medicine Sullivan S verfasserin aut Thompson CC verfasserin aut In Diabetes, Metabolic Syndrome and Obesity Dove Medical Press, 2009 (2017), Seite 311-316 (DE-627)60030597X (DE-600)2494854-8 11787007 nnns year:2017 pages:311-316 https://doaj.org/article/eba2a5da1fe44a2e9a271d5ae0596480 kostenfrei https://www.dovepress.com/the-role-of-endoscopic-therapy-in-obesity-management-intragastric-ball-peer-reviewed-article-DMSO kostenfrei https://doaj.org/toc/1178-7007 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2017 311-316 |
language |
English |
source |
In Diabetes, Metabolic Syndrome and Obesity (2017), Seite 311-316 year:2017 pages:311-316 |
sourceStr |
In Diabetes, Metabolic Syndrome and Obesity (2017), Seite 311-316 year:2017 pages:311-316 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Intragastric balloon aspiration therapy Orbera Reshape Aspire AspireAssist Specialties of internal medicine |
isfreeaccess_bool |
true |
container_title |
Diabetes, Metabolic Syndrome and Obesity |
authorswithroles_txt_mv |
Kumar N @@aut@@ Sullivan S @@aut@@ Thompson CC @@aut@@ |
publishDateDaySort_date |
2017-01-01T00:00:00Z |
hierarchy_top_id |
60030597X |
id |
DOAJ052342662 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ052342662</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310205246.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ052342662</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJeba2a5da1fe44a2e9a271d5ae0596480</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-951</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Kumar N</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nitin Kumar,1 Shelby Sullivan,2 Christopher C Thompson3 1Bariatric Endoscopy Institute, Addison, IL, 2Gastroenterology Bariatric and Metabolic Program, University of Colorado School of Medicine, Denver, CO, 3Gastroenterology and Therapeutic Endoscopy, Brigham and Women&rsquo;s Hospital, Harvard Medical School, Boston, MA, USA Abstract: Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35&ndash;55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used extensively outside the USA for over 20 years. These devices will need to be delivered in the context of a multidisciplinary weight loss program, integrating comprehensive care of obesity. Patient selection is important, and ensuring appropriate patient expectations and understanding of alternatives such as pharmacologic therapy and surgery is essential. With several EBTs on the horizon, patients with obesity will have an even broader array of safe and effective options for weight management in the future. Keywords: intragastric balloon, Orbera, ReShape, AspireAssist, aspiration therapy, weight loss</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Intragastric balloon</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">aspiration therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Orbera</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Reshape</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Aspire</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">AspireAssist</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Specialties of internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sullivan S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thompson CC</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Diabetes, Metabolic Syndrome and Obesity</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2017), Seite 311-316</subfield><subfield code="w">(DE-627)60030597X</subfield><subfield code="w">(DE-600)2494854-8</subfield><subfield code="x">11787007</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2017</subfield><subfield code="g">pages:311-316</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/eba2a5da1fe44a2e9a271d5ae0596480</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/the-role-of-endoscopic-therapy-in-obesity-management-intragastric-ball-peer-reviewed-article-DMSO</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-7007</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2017</subfield><subfield code="h">311-316</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Kumar N |
spellingShingle |
Kumar N misc RC581-951 misc Intragastric balloon misc aspiration therapy misc Orbera misc Reshape misc Aspire misc AspireAssist misc Specialties of internal medicine The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy |
authorStr |
Kumar N |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)60030597X |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC581-951 |
illustrated |
Not Illustrated |
issn |
11787007 |
topic_title |
RC581-951 The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy Intragastric balloon aspiration therapy Orbera Reshape Aspire AspireAssist |
topic |
misc RC581-951 misc Intragastric balloon misc aspiration therapy misc Orbera misc Reshape misc Aspire misc AspireAssist misc Specialties of internal medicine |
topic_unstemmed |
misc RC581-951 misc Intragastric balloon misc aspiration therapy misc Orbera misc Reshape misc Aspire misc AspireAssist misc Specialties of internal medicine |
topic_browse |
misc RC581-951 misc Intragastric balloon misc aspiration therapy misc Orbera misc Reshape misc Aspire misc AspireAssist misc Specialties of internal medicine |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Diabetes, Metabolic Syndrome and Obesity |
hierarchy_parent_id |
60030597X |
hierarchy_top_title |
Diabetes, Metabolic Syndrome and Obesity |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)60030597X (DE-600)2494854-8 |
title |
The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy |
ctrlnum |
(DE-627)DOAJ052342662 (DE-599)DOAJeba2a5da1fe44a2e9a271d5ae0596480 |
title_full |
The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy |
author_sort |
Kumar N |
journal |
Diabetes, Metabolic Syndrome and Obesity |
journalStr |
Diabetes, Metabolic Syndrome and Obesity |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2017 |
contenttype_str_mv |
txt |
container_start_page |
311 |
author_browse |
Kumar N Sullivan S Thompson CC |
class |
RC581-951 |
format_se |
Elektronische Aufsätze |
author-letter |
Kumar N |
author2-role |
verfasserin |
title_sort |
role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy |
callnumber |
RC581-951 |
title_auth |
The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy |
abstract |
Nitin Kumar,1 Shelby Sullivan,2 Christopher C Thompson3 1Bariatric Endoscopy Institute, Addison, IL, 2Gastroenterology Bariatric and Metabolic Program, University of Colorado School of Medicine, Denver, CO, 3Gastroenterology and Therapeutic Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Abstract: Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35–55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used extensively outside the USA for over 20 years. These devices will need to be delivered in the context of a multidisciplinary weight loss program, integrating comprehensive care of obesity. Patient selection is important, and ensuring appropriate patient expectations and understanding of alternatives such as pharmacologic therapy and surgery is essential. With several EBTs on the horizon, patients with obesity will have an even broader array of safe and effective options for weight management in the future. Keywords: intragastric balloon, Orbera, ReShape, AspireAssist, aspiration therapy, weight loss |
abstractGer |
Nitin Kumar,1 Shelby Sullivan,2 Christopher C Thompson3 1Bariatric Endoscopy Institute, Addison, IL, 2Gastroenterology Bariatric and Metabolic Program, University of Colorado School of Medicine, Denver, CO, 3Gastroenterology and Therapeutic Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Abstract: Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35–55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used extensively outside the USA for over 20 years. These devices will need to be delivered in the context of a multidisciplinary weight loss program, integrating comprehensive care of obesity. Patient selection is important, and ensuring appropriate patient expectations and understanding of alternatives such as pharmacologic therapy and surgery is essential. With several EBTs on the horizon, patients with obesity will have an even broader array of safe and effective options for weight management in the future. Keywords: intragastric balloon, Orbera, ReShape, AspireAssist, aspiration therapy, weight loss |
abstract_unstemmed |
Nitin Kumar,1 Shelby Sullivan,2 Christopher C Thompson3 1Bariatric Endoscopy Institute, Addison, IL, 2Gastroenterology Bariatric and Metabolic Program, University of Colorado School of Medicine, Denver, CO, 3Gastroenterology and Therapeutic Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Abstract: Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35–55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used extensively outside the USA for over 20 years. These devices will need to be delivered in the context of a multidisciplinary weight loss program, integrating comprehensive care of obesity. Patient selection is important, and ensuring appropriate patient expectations and understanding of alternatives such as pharmacologic therapy and surgery is essential. With several EBTs on the horizon, patients with obesity will have an even broader array of safe and effective options for weight management in the future. Keywords: intragastric balloon, Orbera, ReShape, AspireAssist, aspiration therapy, weight loss |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
title_short |
The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy |
url |
https://doaj.org/article/eba2a5da1fe44a2e9a271d5ae0596480 https://www.dovepress.com/the-role-of-endoscopic-therapy-in-obesity-management-intragastric-ball-peer-reviewed-article-DMSO https://doaj.org/toc/1178-7007 |
remote_bool |
true |
author2 |
Sullivan S Thompson CC |
author2Str |
Sullivan S Thompson CC |
ppnlink |
60030597X |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
callnumber-a |
RC581-951 |
up_date |
2024-07-04T00:41:57.269Z |
_version_ |
1803607046641156096 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ052342662</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310205246.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ052342662</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJeba2a5da1fe44a2e9a271d5ae0596480</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-951</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Kumar N</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nitin Kumar,1 Shelby Sullivan,2 Christopher C Thompson3 1Bariatric Endoscopy Institute, Addison, IL, 2Gastroenterology Bariatric and Metabolic Program, University of Colorado School of Medicine, Denver, CO, 3Gastroenterology and Therapeutic Endoscopy, Brigham and Women&rsquo;s Hospital, Harvard Medical School, Boston, MA, USA Abstract: Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35&ndash;55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used extensively outside the USA for over 20 years. These devices will need to be delivered in the context of a multidisciplinary weight loss program, integrating comprehensive care of obesity. Patient selection is important, and ensuring appropriate patient expectations and understanding of alternatives such as pharmacologic therapy and surgery is essential. With several EBTs on the horizon, patients with obesity will have an even broader array of safe and effective options for weight management in the future. Keywords: intragastric balloon, Orbera, ReShape, AspireAssist, aspiration therapy, weight loss</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Intragastric balloon</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">aspiration therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Orbera</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Reshape</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Aspire</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">AspireAssist</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Specialties of internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sullivan S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thompson CC</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Diabetes, Metabolic Syndrome and Obesity</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2017), Seite 311-316</subfield><subfield code="w">(DE-627)60030597X</subfield><subfield code="w">(DE-600)2494854-8</subfield><subfield code="x">11787007</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2017</subfield><subfield code="g">pages:311-316</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/eba2a5da1fe44a2e9a271d5ae0596480</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/the-role-of-endoscopic-therapy-in-obesity-management-intragastric-ball-peer-reviewed-article-DMSO</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-7007</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2017</subfield><subfield code="h">311-316</subfield></datafield></record></collection>
|
score |
7.3989134 |